European cardiology最新文献_第9页

Microvascular Angina: Diagnosis and Management. 微血管心绞痛:诊断与治疗。

IF 3

European cardiology Pub Date : 2021-12-02 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.15

Haider Aldiwani, Suzan Mahdai, Ghaith Alhatemi, C Noel Bairey Merz

引用次数: 10

Palpitations in the Cancer Patient. 癌症患者的心悸。

IF 3

European cardiology Pub Date : 2021-12-02 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.44

Hani Essa, Gregory Yh Lip

引用次数: 4

Levosimendan in Europe and China: An Appraisal of Evidence and Context. 左西孟旦在欧洲和中国:证据和背景的评价。

IF 3

European cardiology Pub Date : 2021-11-08 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.41

Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello

引用次数: 0

2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y1₂ Receptor Antagonists in the Asia-Pacific Region: Special Populations. 2021亚太心脏病学会关于在亚太地区使用P2Y12受体拮抗剂的共识建议:特殊人群。

IF 3

European cardiology Pub Date : 2021-11-08 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.35

Jack Wei Chieh Tan, Derek P Chew, Kin Lam Tsui, Doreen Tan, Dmitry Duplyakov, Ayman Hammoudeh, Bo Zhang, Yi Li, Kai Xu, Paul J Ong, Doni Firman, Habib Gamra, Wael Almahmeed, Jamshed Dalal, Li-Wah Tam, Gabriel Steg, Quang N Nguyen, Junya Ako, Jassim Al Suwaidi, Mark Chan, Mohamed Sobhy, Abdulla Shehab, Wacin Buddhari, Zulu Wang, Alan Yean Yip Fong, Bilgehan Karadag, Byeong-Keuk Kim, Usman Baber, Chee Tang Chin, Ya Ling Han

{"title":"2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations.","authors":"Jack Wei Chieh Tan, Derek P Chew, Kin Lam Tsui, Doreen Tan, Dmitry Duplyakov, Ayman Hammoudeh, Bo Zhang, Yi Li, Kai Xu, Paul J Ong, Doni Firman, Habib Gamra, Wael Almahmeed, Jamshed Dalal, Li-Wah Tam, Gabriel Steg, Quang N Nguyen, Junya Ako, Jassim Al Suwaidi, Mark Chan, Mohamed Sobhy, Abdulla Shehab, Wacin Buddhari, Zulu Wang, Alan Yean Yip Fong, Bilgehan Karadag, Byeong-Keuk Kim, Usman Baber, Chee Tang Chin, Ya Ling Han","doi":"10.15420/ecr.2021.35","DOIUrl":"https://doi.org/10.15420/ecr.2021.35","url":null,"abstract":"Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12 inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e43"},"PeriodicalIF":3.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/99/ecr-16-e43.PMC8591619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39764850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis. 秋水仙碱治疗与冠心病患者临床结局的关系:系统评价和荟萃分析

IF 3

European cardiology Pub Date : 2021-10-21 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.31

Francesco Condello, Matteo Sturla, Bernhard Reimers, Gaetano Liccardo, Giulio G Stefanini, Gianluigi Condorelli, Giuseppe Ferrante

{"title":"Association Between Colchicine Treatment and Clinical Outcomes in Patients with Coronary Artery Disease: Systematic Review and Meta-analysis.","authors":"Francesco Condello, Matteo Sturla, Bernhard Reimers, Gaetano Liccardo, Giulio G Stefanini, Gianluigi Condorelli, Giuseppe Ferrante","doi":"10.15420/ecr.2021.31","DOIUrl":"https://doi.org/10.15420/ecr.2021.31","url":null,"abstract":"Background: The authors examined the association between colchicine treatment and clinical outcomes in patients with coronary artery disease. Methods: They performed a meta-analysis of randomised controlled trials (RCTs) involving patients with coronary artery disease receiving addon colchicine to standard treatment compared with standard treatment. They used a mixed-effects Poisson regression model with random intervention effects to estimate the pooled incidence rate ratios (IRR) with 95% CI. Results: Ten RCTs were identified, including 12,819 participants followed up for a median of 6 months. Colchicine was associated with a lower risk of major adverse cardiovascular events (IRR 0.69; 95% CI [0.60-0.79]; number needed to treat for an additional beneficial outcome [NNTB] = 28); MI (IRR 0.77; 95% CI [0.64-0.93]; NNTB = 95) and ischaemic stroke (IRR 0.48; 95% CI [0.30-0.76]; NNTB = 155) and with a higher risk of gastrointestinal adverse events (IRR 1.69; 95% CI [1.12-2.54]; number needed to treat for an additional harmful outcome [NNTH] = 10). Colchicine did not affect all-cause death (IRR 1.09; 95% CI [0.85-1.40]), or cardiovascular death (IRR 0.75; 95% CI [0.51-1.12]), while it was associated with a higher risk of non-cardiovascular death (IRR 1.45; 95% CI [1.04-2.02]; NNTH = 396). Conclusion: The meta-analysis showed that the relative and absolute beneficial treatment effects of colchicine on cardiovascular outcomes outweigh the potential harm for non-cardiovascular mortality. Registration: PROSPERO 2021 CRD42021248874.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e39"},"PeriodicalIF":3.0,"publicationDate":"2021-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/a0/ecr-16-e39.PMC8576482.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39876828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Hypertension in Women: Should There be a Sex-specific Threshold? 女性高血压:应该有一个性别特异性阈值吗?

IF 3

European cardiology Pub Date : 2021-10-18 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.17

Eva Gerdts, Giovanni de Simone

引用次数: 7

The Role of Mental Stress in Ischaemia with No Obstructive Coronary Artery Disease and Coronary Vasomotor Disorders. 精神应激在缺血性无阻塞性冠状动脉疾病和冠状动脉血管舒缩障碍中的作用。

IF 3

European cardiology Pub Date : 2021-10-12 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.20

Roos Et van der Meer, Angela Hem Maas

{"title":"The Role of Mental Stress in Ischaemia with No Obstructive Coronary Artery Disease and Coronary Vasomotor Disorders.","authors":"Roos Et van der Meer, Angela Hem Maas","doi":"10.15420/ecr.2021.20","DOIUrl":"https://doi.org/10.15420/ecr.2021.20","url":null,"abstract":"Ischaemic heart disease has been estimated to affect 126.5 million people globally. Approximately 70% of patients with angina and suspected myocardial ischaemia show no signs of obstructed coronary arteries after coronary angiography, but may still demonstrate ischaemia. Ischaemia with no obstructive coronary artery disease (INOCA) is increasingly acknowledged as a serious condition because of its association with poor quality of life and elevated risk for cardiovascular events. The negative effects of psychological stress on INOCA are gaining more attention. Psychological stress is associated with adverse cardiovascular outcomes such as mental stress-induced myocardial ischaemia. Psychological stress includes anxiety, depression, anger and personality disturbances. Coronary microvascular dysfunction and coronary arterial spasm are phenotypes of coronary vasomotor disorders that are triggered by psychological distress and depression, thereby increasing cardiovascular disease risk. Coronary vasomotor disorders are often co-existent in INOCA patients and might be considered as a contributing factor to mental stress-associated adverse cardiovascular outcomes. Additionally, psychological stress induces endothelial dysfunction more often in (young) women with INOCA than in men. Overall, many studies demonstrate an association between mental stress, coronary microvascular dysfunction and coronary vasospasm in patients with INOCA - especially women. Future research on stress-reducing therapies that target coronary vasomotor disorders in patients with INOCA is needed. This is particularly the case in young adolescents, in whom this type of ischaemic heart disease is increasing.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e37"},"PeriodicalIF":3.0,"publicationDate":"2021-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/4e/ecr-16-e37.PMC8532004.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39668064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review. 新的心血管生物标志物与既往子痫前期/HELLP综合征女性心血管风险增加相关:一项叙述性综述

IF 3

European cardiology Pub Date : 2021-09-24 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.21

Esmee Me Bovee, Martha Gulati, Angela Hem Maas

{"title":"Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review.","authors":"Esmee Me Bovee, Martha Gulati, Angela Hem Maas","doi":"10.15420/ecr.2021.21","DOIUrl":"https://doi.org/10.15420/ecr.2021.21","url":null,"abstract":"Evidence has shown that women with a history of preeclampsia or haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome have an increased risk of cardiovascular disease later in life. Recommendations for screening, prevention and management after such pregnancies are not yet defined. The identification of promising non-traditional cardiovascular biomarkers might be useful to predict which women are at greatest risk. Many studies are inconsistent and an overview of the most promising biomarkers is currently lacking. This narrative review provides an update of the current literature on circulating cardiovascular biomarkers that may be associated with an increased cardiovascular disease risk in women after previous preeclampsia/HELLP syndrome. Fifty-six studies on 53 biomarkers were included. From the summary of evidence, soluble fms-like tyrosine kinase-1, placental growth factor, interleukin (IL)-6, IL-6/IL-10 ratio, high-sensitivity cardiac troponin I, activin A, soluble human leukocyte antigen G, pregnancy-associated plasma protein A and norepinephrine show potential and are interesting candidate biomarkers to further explore. These biomarkers might be potentially eligible for cardiovascular risk stratification after preeclampsia/HELLP syndrome and may contribute to the development of adequate strategies for prevention of hypertension and adverse events in this population.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":" ","pages":"e36"},"PeriodicalIF":3.0,"publicationDate":"2021-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/00/ecr-16-e36.PMC8546910.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39668062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Transcatheter Aortic Valve Implantation and Subclinical and Clinical Leaflet Thrombosis: Multimodality Imaging for Diagnosis and Risk Stratification. 经导管主动脉瓣植入与亚临床和临床小叶血栓形成:多模态成像诊断和风险分层。

IF 3

European cardiology Pub Date : 2021-09-24 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.09

María Martín, Javier Cuevas, Helena Cigarrán, Juan Calvo, César Morís

引用次数: 8

Coronavirus Disease 2019: Psychological Stress and Cardiovascular Diseases. 2019冠状病毒病:心理压力和心血管疾病。

IF 3

European cardiology Pub Date : 2021-09-14 eCollection Date: 2021-02-01 DOI: 10.15420/ecr.2021.10

Maki Komiyama, Koji Hasegawa

引用次数: 11